Pain Relief Patchs

Camphor, Menthol, Methyl Salicylate


Anhui Miao De Tang Pharmaceutical Co., Ltd.
Human Otc Drug
NDC 81484-201
Pain Relief Patchs also known as Camphor, Menthol, Methyl Salicylate is a human otc drug labeled by 'Anhui Miao De Tang Pharmaceutical Co., Ltd.'. National Drug Code (NDC) number for Pain Relief Patchs is 81484-201. This drug is available in dosage form of Patch. The names of the active, medicinal ingredients in Pain Relief Patchs drug includes Camphor (synthetic) - 3.8 g/1 Menthol - 5.2 g/1 Methyl Salicylate - 3.1 g/1 . The currest status of Pain Relief Patchs drug is Active.

Drug Information:

Drug NDC: 81484-201
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Pain Relief Patchs
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Camphor, Menthol, Methyl Salicylate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Anhui Miao De Tang Pharmaceutical Co., Ltd.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Patch
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAMPHOR (SYNTHETIC) - 3.8 g/1
MENTHOL - 5.2 g/1
METHYL SALICYLATE - 3.1 g/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 07 Apr, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Anhui Miao De Tang Pharmaceutical Co., Ltd.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:5TJD82A1ET
L7T10EIP3A
LAV5U5022Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
81484-201-022 BAG in 1 BOX (81484-201-02) / 5 PATCH in 1 BAG (81484-201-01)07 Apr, 2021N/ANo
81484-201-0310 PATCH in 1 BOX (81484-201-03)07 Apr, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose topical analgesic, pain relief patch

Product Elements:

Pain relief patchs camphor, menthol, methyl salicylate natural latex rubber lanolin borneol petrolatum methyl salicylate salicylic acid rosin menthol menthol camphor (synthetic) camphor (synthetic)

Indications and Usage:

Use use to the adjuvant treatment of pain caused by cervical spondylosis, frozen shoulder, lumbar disc herniation, rheumatoid arthritis, and bone or joint or soft tissue injury.

Warnings:

Warnings for external use only.

Do Not Use:

Warnings for external use only.

When Using:

Use only as directed avoid contact with eyes, mucous membranes or rashes do not bandage tightly do not use at the same time as other topical analgesics dispose of used patch in manner that keeps product away from children and pets. used patches still contain the drug product that can produce serious adverse effects if a child or pet chews or ingests this patch.

Dosage and Administration:

Directions for temporary relief of minor aches and pains. ?

Stop Use:

If rash, itching or excessive skin irritation develops if condition worsens if symptoms last more than 7 days or clear up and occur again with a few days

Package Label Principal Display Panel:

Package label - principal display panel label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.